DS
CTMX icon

DRW Securities’s CytomX Therapeutics CTMX Stock Holding History

DRW Securities’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Buy
34,569
+12,766
+59% +$48.7K ﹤0.01% 850
2026
Q1 		$102K Buy
+21,803
New +$111K ﹤0.01% 1183

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

DRW Securities's CTMX Position: Q2 2026 in Review

DRW Securities increased its CytomX Therapeutics (CTMX) stake by 59% in Q2 2026, buying an estimated $48.7K and bringing the position to 34,569 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #850.

DRW Securities first reported a position in CTMX in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • DRW Securities held 34,569 shares of CytomX Therapeutics worth $130K as of Q2 2026.
  • DRW Securities bought 12,766 CytomX Therapeutics shares in Q2 2026, an estimated $48.7K.
  • CytomX Therapeutics made up ﹤0.01% of DRW Securities's portfolio in Q2 2026, its #850 holding.
  • DRW Securities first reported a position in CytomX Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.